secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001549595-25-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation
--------------------------------------------------------------------------------

- Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.
- Cash & marketable securities $549.7M at Feb 28, 2025; down from $609.6M at Nov 30, 2024.
- Earned $7M milestones in quarter; post-quarter received $15M license extension fee from Sanofi.
- NX-5948 named bexobrutideg; FDA Orphan Drug for Waldenström macroglobulinemia; pivotal trials in CLL on track for 2025.
- Added Roy Baynes to board and John Northcott as CCO; Sanofi exercised option to license undisclosed inflammation target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/0001549595-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/nrix-20250408.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer